Optimizing treatment sequencing in multiple myeloma: a novel model to predict survival outcomes
Objective Patients with multiple myeloma (MM) typically require multiple regimens and become harder to treat with each line of treatment. Furthermore, there is a lack of direct comparative clinical trial data to guide effective treatment sequencing. A novel model is described comparing alternative M...
        Saved in:
      
    
          | Main Authors: | Maria Teresa Petrucci, Sara Bringhen, Cristina Entrala Cerezo, João Mendes, Patrizio Armeni | 
|---|---|
| Format: | Article | 
| Language: | English | 
| Published: | Taylor & Francis Group
    
        2024-12-01 | 
| Series: | Hematology | 
| Subjects: | |
| Online Access: | https://www.tandfonline.com/doi/10.1080/16078454.2024.2432815 | 
| Tags: | Add Tag 
      No Tags, Be the first to tag this record!
   | 
Similar Items
- 
                
                    REAL WORLD MULTIPLE MYELOMA REGISTRY FROM JORDAN, A DEVELOPING COUNTRY.         
                          
 by: Abdalla Awidi, et al.
 Published: (2022-04-01)
- 
                
                    Front‐line treatment efficacy and clinical outcomes of elderly patients with multiple myeloma in a real‐world setting: A multicenter retrospective study in China        
                          
 by: Li Bao, et al.
 Published: (2023-02-01)
- 
                
                    Time to progression predicts outcome of patients with multiple myeloma that can be influenced by autologous hematopoietic stem cell transplantation        
                          
 by: Yanhua Yue, et al.
 Published: (2025-12-01)
- 
                
                    Severe and continuous immunoparesis during induction or maintenance therapy in nontransplant patients with multiple myeloma is a sign of poor prognosis        
                          
 by: Ying Chen, et al.
 Published: (2024-12-01)
- 
                
                    PHF19 before and post induction treatment possess favorable potency of reflecting treatment response to protease inhibitors, event-free survival, and overall survival in multiple myeloma patients        
                          
 by: Hongyu An, et al.
 Published: (2024-12-01)
 
       